Sources Contact Advanced Search Tutorials

An Interest In:

Web News this Week

Search Archive

Some of Our Sources

View All Sources

Help Webnuz

Referal links:

January 10, 2020 11:20 pm

23andMe Licenses Antibody It Developed From its Genetic Database To Spanish Firm Almirall

23andMe has licensed an antibody it developed from its genetic database to treat inflammatory diseases to Spanish drugmaker Almirall SA. "The deal, announced by Almirall in a filing with Spanish regulators on Thursday, marks the first time that 23andMe has licensed a drug compound that it has developed itself," reports Bloomberg. From the report: Leveraging its genetic data to develop drugs has become an increasingly important part of 23andMe's business. More than 10 million customers have taken its DNA tests, and that trove of data can help illuminate new drug targets to treat disease. Previously, the company had made a deal to share its data and collaborate on drug development with U.K. drugmaker GlaxoSmithKline Plc, which took a $300 million stake in the company in 2018. But this is the first time it has licensed a compound it has developed in-house. The compound belongs to a class of large-molecule drugs designed to target a single protein in the body, what's known as a bispecific monoclonal antibody. That antibody is designed to block signals from a family of proteins known as IL-36 cytokine that is associated with many autoimmune and inflammatory conditions, such as lupus and Crohn's disease. 23andMe was most interested in the antibody's effectiveness to treat severe forms of psoriasis. The company put the drug compound through animal testing but it will still need to undergo clinical trials in humans.

Slashdot

Slashdot was originally created in September of 1997 by Rob "CmdrTaco" Malda. Today it is owned by Geeknet, Inc..

More About this Source Visit Slashdot